Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

Affiliations

• ¹ Dana-Farber Cancer Institute, Boston, MA.
• ² CLL Research Consortium, Moores Cancer Center, UC San Diego Health, La Jolla, CA.
• ³ University of Texas MD Anderson Cancer Center, Houston, TX.
• ⁴ Clearview Cancer Institute, Huntsville, AL.
• ⁵ David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA.
• ⁶ Fred Hutchinson Cancer Research Center, Seattle, WA.
• ⁷ Department of Medicine, University of Washington, Seattle, WA.
• ⁸ Genentech, Inc, South San Francisco, CA.
• ⁹ Roche Products Ltd, Welwyn, United Kingdom.
• ¹⁰ F. Hoffmann-La Roche Ltd, Basel, Switzerland; and.
• ¹¹ Department of Medicine, Moores Cancer Center, UC San Diego Health, La Jolla, CA.